🔗 Permalink

Assignee profile:

ASCENDIS PHARMA GROWTH DISORDERS A/S

City:

Hellerup

Country:

Denmark

Published Applications:

Last publication date:

2025-03-20

Patent Grants:

Last grant date:

2026-06-30

Top Inventors for applications by ASCENDIS PHARMA GROWTH DISORDERS A/S

These are the the leading inventors for applications assigned to ASCENDIS PHARMA GROWTH DISORDERS A/S:

Ulrich Hersel 16 Heidelberg, Germany
Harald Rau 15 Dossenheim, Germany
Felix CLEEMANN 14 Mainz, Germany
Kennett Sprogøe 13 Holte, Denmark

Caroline Elisabeth Rasmussen 9 Virum, Denmark
Thomas Wegge 5 Heidelberg, Germany
Ana Bernhard 4 Heidelberg, Germany
Kennett SPROGØE 4 Holte, Denmark

Frank FALTINGER 3 Heidelberg, Germany
Lars Holten-Andersen 2 Vanløse, Denmark
Tom WOODS 2 Weinheim, Germany
Vibeke Miller BREINHOLT 2 Frederiksberg, Denmark

Nora Kaluza 2 Munich, Germany
Annette BUBA 2 Kaiserslautern, Germany
Charlotte PINHOLT 1 Hellerup, Denmark
Stefan HEINIG 1 Heidelberg, Germany

Felix Cleenmann 1 Mainz, Germany
Anja R. H. Skands 1 Hellerup, Denmark
Anja R.H. SKANDS 1 Hellerup, Denmark

Recent patent applications by ASCENDIS PHARMA GROWTH DISORDERS A/S

ASCENDIS PHARMA GROWTH DISORDERS A/S based in Hellerup, DK has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-03-20

US20250090671A1

Human necessities

CNP PRODRUGS

#2 | 2023-09-28 ✅ Patent 12,667,604 granted on 2026-06-30

US20230302091A1

Human necessities

Combination Therapy with Controlled-Release CNP Agonists

#3 | 2023-04-06 ✅ Patent 12,239,689 granted on 2025-03-04

US20230103820A1

Human necessities

Controlled-release CNP agonists with low initial NPR-B activity

#4 | 2022-12-29 ✅ Patent 12,544,428 granted on 2026-02-10

US20220409700A1

Human necessities

CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS

#5 | 2022-10-20 ✅ Patent 12,156,917 granted on 2024-12-03

US20220331438A1

Human necessities

CNP prodrugs with carrier attachment at the ring moiety

#6 | 2022-09-22

US20220296682A1

Human necessities

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

#7 | 2022-04-21 ✅ Patent 12,377,133 granted on 2025-08-05

US20220118053A1

Human necessities

Dry Pharmaceutical Formulations of CNP Conjugates

#8 | 2022-03-24 ✅ Patent 12,083,182 granted on 2024-09-10

US20220088206A1

Human necessities

Controlled-release CNP agonists with increased NEP stability

#9 | 2021-06-17 ✅ Patent 11,154,593 granted on 2021-10-26

US20210177942A1

Human necessities

CNP prodrugs with large carrier moieties

#10 | 2021-03-11

US20210069339A1

Human necessities

CNP PRODRUGS

#11 | 2020-09-03 ✅ Patent 11,564,974 granted on 2023-01-31

US20200276270A1

Human necessities

Combination therapy with controlled-release CNP agonists

#12 | 2019-10-31 ✅ Patent 11,389,511 granted on 2022-07-19

US20190328841A1

Human necessities

Controlled-release CNP agonists with reduced side-effects

#13 | 2019-10-31 ✅ Patent 11,389,510 granted on 2022-07-19

US20190328840A1

Human necessities

Controlled-release CNP agonists with low initial NPR-B activity

#14 | 2019-08-22

US20190255183A1

Human necessities

CNP PRODRUGS

#15 | 2019-01-24 ✅ Patent 11,224,661 granted on 2022-01-18

US20190022237A1

Human necessities

Controlled-release CNP agonists with increased NEP stability

#16 | 2019-01-17 ✅ Patent 10,835,578 granted on 2020-11-17

US20190015481A1

Human necessities

CNP prodrugs with large carrier moieties

#17 | 2019-01-10 ✅ Patent 11,413,351 granted on 2022-08-16

US20190008977A1

Human necessities

CNP prodrugs with carrier attachment at the ring moiety

#18 | 2019-01-03 ✅ Patent 11,311,604 granted on 2022-04-26

US20190000926A1

Human necessities

Controlled-release CNP agonists with low NPR-C binding

Also check out ASCENDIS PHARMA GROWTH DISORDERS A/S's (Hellerup, Denmark) applicant profile with 24 patent applications submitted.

AssigneeID:

143817 ⎘